Moles and melanoma

Current Opinion in Pediatrics

Volumn 10, Issue 4, 1998, Pages 398-404

  Chamlin, Sarah L ^a   Williams, Mary L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; SUNSCREEN;

ADJUVANT THERAPY; ADOLESCENT; CANCER RISK; CHILD; CONGENITAL NEVUS; HEALTH EDUCATION; HUMAN; INFANT; LASER SURGERY; MELANOMA; NERVOUS SYSTEM; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; PROTECTIVE CLOTHING; RADIATION EXPOSURE; REVIEW; RISK FACTOR; SCHOOL CHILD; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION;

EID: 0031659869     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-199808000-00013     Document Type: Review

References (80)

1. Rigel DS, Freidman RJ, Kopf AW: The incidence of malignant melanoma in the United States: Issues as we approach the 21st century. J Am Acad Dermatol 1996, 34:839-847. This paper emphasizes that the melanoma "epidemic" is 1) worldwide, among persons of Caucasion skin type; 2) not attributable to increased sensitivity of diagnosis or change in criteria; and 3) accompanied by a rise in mortality due to melanoma. In men, the prevalence melanoma is increasing faster than that of any other cancer; in women, it is second only to the rising risk of lung cancer. Non-dermatologists need to improve their diagnostic skills with pigmented lesions.
2. Berg P, Lindelof B: Differences in malignant melanoma between children and adolescents. Arch Dermatol 1997, 133:295-297. Using data from the compulsory Swedish Cancer registry, the authors found that the incidence of melanoma among adolescents (14-20 years) had doubled over the past 10 years, while the incidence in children less than 14 years old was unchanged. This study underscores the need for all physicians, including pediatricians, to become aware of the warning signs of melanoma.
3. Williams ML, Pennella R: Melanoma, melanocytic nevi, and other melanoma risk factors in children. J Pediatr 1994, 124:833-845.
4. Esterly NB et al.: Management of congenital melanocytic nevi: A decade later. Pediatric Dermatol 1996, 13:321-340. This symposium features brief essays from experts around the world concerning their interpretation of the melanoma risks associated with congenital melanocytic nevi and their approach to the management of these lesions. Most quote the same literature but come to varying opinions about their significance. Where there is a lack of data, opinion flourishes.
5. Kopf AW, Levine LJ, Rigel DS, et al.: Prevalence of congenital-nevus-like nevi, nevi spili, and café au lait spots. Arch Dermatol 1985, 121:766-769.
6. Clemmenson OJ, Kroon S: The histology history of "congenital features" in early acquired melanocytic nevi. J Am Acad Dermatol 1988, 19:742-764.
7. Sigg C, Pelloni F, Schyder UW: Frequency of congenital nevi, nevi spili, and café-au-lait spots and their relation to nevus count and skin complexion in 939 children. Dermatologica 1990, 180:118-123.
8. MacKie RM, Watt D, Doherty V, Aitchison TC: Malignant melanoma occurring in those aged under 30 in the west of Scotland 1976-1986: A study of incidence, clinical features, pathological features and survival. Br J Dermatol 1991, 124:560-564.
9. Rhodes AR, Sober AJ, Day CL, Nickel WR: The malignant potential of small congenital nevocellular nevi: an estimate of association based on a histological study of 234 primary cutaneous melanomas. J Am Acad Dermatol 1982, 6:230-241.
10. Rhodes AR, Melski JW: Small congenital nevocellular nevi and the risk of cutaneous melanoma. J Pediatr 1982, 100:219-224.
11. Harley S, Walsh N: A new look at nevus-associated melanomas. Am J Dermatopathology 1996, 18:137-141.
12. Shpall S, Frieden IJ, Newman T, Chesney M: Risk of malignant transformation of congenital nevi in blacks. Pediatr Dermatol 1994, 11:204-208.
13. Castilla EE, de Graca M, Orioli-Parreiras IM: Epidemiology of congenital pigmented naevi: Incidence rates and relative frequencies. Br J Dermatol 1981, 104:307-315.
14. Marghoob AA, Schoenbach SP, Kopf AW: Large congenital melanocytic nevi and the risk for the development of malignant melanoma. Arch Dermatol 1996, 132:170-175. The authors examine the development of melanoma among patients with large congenital nevi prospectively enrolled in a registry. A 5-year risk of 4.5% was derived; a risk that is more than 200-fold greater than in the general population.
15. Kadonaga JN, Frieden IJ: Neurocutaneous melanosis: Definition and review of the literature. J Am Acad Dermatol 1991, 24:745-747.
16. DeDavid M, Orlow SJ, Provost N: Neurocutaneous melanosis: Clinical features of large congenital melanocytic nevi in patients with manifest central nervous system melanosis. J Am Acad Dermatol 1996, 35:529-538. This review examines 289 patients with large melanocytic nevi, about two fifths deriving from a prospective registry of giant nevi and about three fifths from a literature review. Of these 289, 33 had central nervous system melanosis. Patients with posterior axial lesions have an increased risk for neurocutaneous melanosis, especially if associated with multiple satellite nevi. Magnetic resonance evaluation of the central nervous system should be considered in these patients.
17. Frieden IJ, Williams ML, Barkovich AJ: Giant congenital melanocytic nevi: Brain magnetic resonance findings in neurologically asymptomatic children. J Am Acad Dermatol 1994, 31:423-429.
18. Cohen MC, Kaschula ROC, Drut R: Pluripotential melanoblastoma, a unifying concept on malignancy arising in congenital melanocytic nevi: Report of two cases. Pediatr Pathol Lab Med 1996, 16:801-812.
19. DeDavid M, Orlow SJ, Provost N: A study of large congenital melanocytic nevi and associated malignant melanomas: Review of cases in the New York University Registry and the world literature. J Am Acad Dermatol 1997, 36:409-416. The same database of 289 patients with large congenital melanocytic nevi is examined for associated malignancies. Thirty-four (12%) patients had primary cutaneous melanoma; in 2 patients the melanoma developed at extracutaneous sites. Other neural crest and mesenchymal tumors also occurred in 13 patients. The incidence of malignancy in axial nevi seems to be greater than in extremity nevi, although the latter are much less common and this observation may not hold. Importantly, melanoma was never observed arising from satellite nevi.
20. Gibstein LA, Abramson DL, Bartlett RA, et al.: Tissue expansion in children: A retrospective study of complications. Ann Plast Surg 1997, 38:358-364. Tissue expansion is now commonly employed in the surgical approach to large congenital nevi. The rate of complication in 105 patients reviewed is 19% and includes infection, deflation, and exposure.
21. Rompel R, Moser M, Petres J: Dermabrasion of congenital nevocellular nevi: experience in 215 patients. Dermatology 1997, 194:261-267. Dermabrasion of congenital nevi, particularly when undertaken in the neonatal period, is efficacious in reducing pigmentation in most patients. Unfortunately, melanomas have been reported to arise from residual nevus following partial thickness excisions, hence whether partial excision methods offer more than cosmetic benefit remains to be determined.
22. De Raeve LE, De Coninck AL, Dierickx PR: Neonatal curettage of giant congenital melanocytic nevi. Arch Dermatol 1996, 132:20-22. Curettage was performed on four newborns with giant congenital nevi during the first 2 weeks of life. Pigment was reduced in all patients, but whether the melanoma risk will be correspondingly reduced is unknown.
23. Rhodes AR, Wood WC, Sober AJ, Mihm MC Jr: Nonepidermal origin of malignant melanoma associated with a giant congenital nevocellular nevus. Plast Reconstruct Surg 1981, 67:782-790.
24. Waldorf HA, Kauvar AN, Geronemus RG: Treatment of small and medium congenital nevi with the Q-switched ruby laser. Arch Dermatol 1996, 132:301-304. Congenital nevi in 18 prepubertal children were treated with the Q-switched ruby laser. Pigmentation was reduced by an average of 50%, but partial repigmentation usually occurred within 6 months. With further improvements in the technology, the primary application of laser therapy may be to enhance the appearance of low-risk lesions, such as satellite nevi in children with giant congenital nevi. Because the technique cannot provide tissue for histopathology, it will always be inappropriate when there is any suspicion of malignancy.
25. Grevelink JM, van Leeuwen RL, Anderson RR, Byers HB: Clinical and histological responses of congenital melanocytic nevi after single treatment with Q-switched lasers. Arch Dermatol 1997, 133:349-353.
26. Ueda S, Imayama S: Normal mode ruby laser for treating congenital nevi. Arch Dermatol 1997, 133:355-359.
27. Goldberg DJ, Stampien T: Q-switched ruby laser treatment of congenital nevi. Arch Dermatol 1995, 131:621-622.
28. Luther H, Altmeyer P, Garbe C, et al.: Increase of melanocytic nevi counts in children during 5 years of follow-up and analysis of associated factors. Arch Dermatol 1996, 132:1473-1478. A group of 357 German children were examined and their nevi were counted in kindergarten and 5 years later. Light skin pigmentation and sun exposure were both linked to an increase in nevus counts.
29. Gallagher RP, McLean DI, Yang CP: Suntan, sunburn, and pigmentation factors and the frequency of acquired melanocytic nevi in children. Arch Dermatol 1990, 126:770-776.
30. Pope DJ, Sorahan T, Marsden JR, et al.: Benign pigmented nevi in children: Prevalence and associated factors. The West Midlands, United Kingdom mole study. Arch Dermatol 1992, 128:1201-1206.
31. Gallagher RP, Mclean DI, Yang CP: Anatomic distribution of acquired melanocytic nevi in white children. Arch Dermatol 1990, 125:466-471.
32. Rampen FHJ, Van der Meeren HLM, Boezeman JBM: Frequency of moles as a key to melanoma incidence? J Am Acad Dermatol 1986, 15:1200-1203.
33. Easton DF, Cox GM, MacDonald AM, Ponder BAJ: Genetic susceptibility to naevi: A twin study. Br J Cancer 1991, 64:1164-1167.
34. Smith CH, McGregor JM, et al.: Excess melanocytic nevi in children with renal allografts. J Am Acad Dermatol 1993, 28:51-55.
35. Green A, Smith P, McWhorter W, et al.: Melanocytic naevi and melanoma in survivors of childhood cancer. Br J Cancer 1993, 67:1053-1057.
36. Weinstock MA, Barnhill RL, Rhodes AR, Brodsky GL, et al.: Reliability of the histopathologic diagnosis of melanocytic dysplasia. Arch Dermatol 1997, 133:953-958. The histopathologic criteria used to diagnose melanocytic dysplasia have varied from center to center, resulting in controversy and recommendations by some to abandon the entire concept. This paper demonstrates that using predetermined criteria for intraepidermal melanocytic atypia, dermatopathologists can reproducibly grade degrees of melanocytic dysplasia in biopsies.
37. Kopf AW, Friedman RJ, Rigel DS: Atypical mole syndrome. J Am Acad Dermatol 1990, 22:117-118.
38. Schneider JS, Moore DH 2nd, Sagebiel RW: Risk factors for melanoma incidence in prospective follow-up. The importance of atypical (dysplastic) nevi. Arch Dermatol 1994, 130:1002-1007.
39. Tucker MA, Halpem A, Holly EA, Hartge P, Elder DE, Sagebiel RW, Guerry D IV, Clark WH Jr: Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA 1997, 227:1439-1444. This case-controlled study enrolled sufficient patients to allow the investigators to separately assess the risk of melanoma associated with having atypical nevi vs. having numerous common nevi. Although earlier studies had suggested that these were separate risk factors, they tend to occur in the same patients (ie, patients with atypical moles tend to have lots of moles) and it was difficult to evaluate their separate contributions to melanoma risk. In this study, atypical (ie, clinically dysplastic nevi) were most strongly associated with melanoma risk; one atypical nevus conferred a two-fold increased relative risk, and 10 or more conferred a 12-fold increased risk; whereas the magnitude of risk associated with numerous common nevi was two-to four-fold. Interestingly, congenital nevus-like nevi in this study were not associated with melanoma risk.
40. Greene MH: Genetics of cutaneous melanoma and nevi. Mayo Clin Proc 1997, 72:467-474. The controversies surrounding the genetics of melanoma and dysplastic nevi are reviewed. There are probably multiple loci for dominantly inherited familial melanoma. There is evidence that dysplastic nevi (outside of familial melanoma kindreds) are also dominantly inherited, although whether the same loci that determine melanoma are involved is not known. The author also reviews the literature that demonstrates that an abnormal mole pattern with dysplastic or atypical nevi is a strong clinical predictor of melanoma risk.
41. Bale SJ, Dracopoli NC, Tucker MA, et al.: Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome 1p. N Engl J Med 1989, 320:1367-1372.
42. Cannon-Albright LA, Goldgar DE, Meyer LJ, et al.: Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science 1992, 258:1148-1152.
43. Tucker MA, Greene MH, Clark WH, et al.: Dysplastic nevi on the scalp of prepubertal children from melanoma-prone families. J Pediatr 1983, 103:65-70.
44. Greene MH, Clark WH Jr, Tucker MA, et al.: High risk of malignant melanoma in melanoma prone families with dysplastic nevi. Ann Intern Med 1985, 102:458-465.
45. Handfield-Jones SE, Smith NP: Malignant melanoma in childhood. Br J Dermatol 1996, 34:607-616. A retrospective review from the UK of 24 children with melanoma, examining the histopathology, clinical features, and outcome. The authors emphasize that Spitz-like features were present in several and the histopathologic distinction between the benign Spitz nevus and melanoma can be very challenging.
46. Piepkorn M: On the nature of histological observations: The case of the Spitz nevus. J Am Acad Derm 1995, 32:248-254.
47. Casso EM, Grin-Jorgensen CM, Grant-Kels JM: Spitz nevi. J Am Acad Dermatol 1992, 27:901-913.
48. Friedman RJ, Rigel DS, Silverman MK, Kopf AW, Vossaert KA: Malignant melanoma in the 1990's: The continued importance of early detection and the role of physician examination and self-examination of the skin. CA Cancer J Clin 1991, 41:201-226.
49. Ruiz-Maldonado R, de la Luz Orozco-Covarrubias M: Malignant melanoma in children. Arch Dermatol 1997, 133:363-371. A comprehensive and well-referenced recent review of childhood melanoma that includes discussion of risk factors and precursor lesions. The authors note that melanoma in the prepubertal child perhaps as much as half of the time arises de novo, that is, as nodular melanoma, whereas melanoma in adolescents, like in adults, presents with the variable color and shape of superficial spreading melanomas.
50. Egan CA, Bradley RR, Logsdon VK, Summers BK: Vulvar melanoma in childhood. Arch Dermatol 1997, 133:345-348.
51. Wu SJ, Lambert DR: Melanoma in children and adolescents. Pediatr Dermatol 1997, 14:87-92.
52. Chen YT, Dubrow B, Holford TR, et al.: Malignant melanoma risk factors by anatomic site: A case-control study and polychotomous logistic regression analysis. Int J Cancer 1996, 67:636-643. In this study, melanomas are not only linked to a history of sunburns, but their site of origin is the same.
53. Whiteman DC, Valery P, McWhirter, Green AC: Risk factors for childhood melanoma in Queensland, Australia. Int J Cancer 1997, 70:26-31. A case-controlled study of melanoma risk factors in 61 Australian children aged 15 years or less with melanoma. The presence of numerous (>10), large (>5 mm) nevi, heavy facial freckling (evidence of excessive skin exposure for skin type), light skin type, and a family history of melanoma were all significantly more common in case than control subjects. The study provides the first evidence that the major risk factors for adult melanoma may also be predictive of childhood risk.
54. Novakovic B, Clark WH Jr, Fears TR, et al.: Melanocytic nevi, dysplastic nevi, and malignant melanoma in children from melanoma-prone families. J Am Acad Dermatol 1995, 33:631-636.
55. Rodriguez-Galindo C, Pappo AS, Kaste SC, ef al.: Brain metastases in children with melanoma. Cancer 1997, 79:2440-2445.
56. Veronesi U, Cascinelli N: Narrow excision (1-cm margin): A safe procedure for thin cutaneous melanoma. Arch Surg 1991, 126:438-441.
57. Ho VC, Sober AJ: Therapy for cutaneous melanoma: An update. J Am Acad Dermatol 1990, 22:159-176.
58. Brady MS, Coit DG: Sentinel lymph node evaluation in melanoma. Arch Dermatol 1997, 133:1014-1020. The techniques of lymphatic mapping and sentinel lymph node biopsy, and controversies surrounding their use are reviewed.
59. Piepkom M, Weinstock MA, Barnhill RL: Theoretical and empirical arguments in relation to elective lymph node dissection for melanoma. Arch Dermatol 1997, 133:995-1002.
60. Demierre MF, Koh HK: Adjuvant therapy for cutaneous malignant melanoma. J Am Acad Dermatol 1997, 36:747-764. This comprehensive review analyzes data from randomized trials of adjuvant therapy for melanoma and discusses the rationale for its use.
61. Dickler MN, Coit DG, Meyers ML: Adjuvant therapy of malignant melanoma. Surg Oncol Clin North Am 1997, 6:793-812.
62. Johnson TM, Smith JW, Nelson BR, Chang A: Current therapy for cutaneous melanoma. J Am Acad Dermatol 1995, 32:689-706.
63. Hansson J: Systemic therapy of malignant melanoma. Med Oncol 1997, 14:73-81.
64. Berwick M, Dubin N, Luo ST, Flannery J: No improvement in survival from melanoma diagnosed from 1973 to 1984. Int J Epidemiol 1994, 23:673-681.
65. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, et al.: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol 1996, 14:7-17. The use of interferon alpha-2b in high-risk melanoma patients improves disease-free survival. This benefit is greatest in node-positive individuals. Toxiciry of this therapy is significant but tolerable to most patients, with 9% of individuals experiencing life-threatening toxicity.
66. Creagan ET, Dalton RJ, Ahmann DL, Jung SH, et al.: Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 1995, 13:2776-2783.
67. Legha SS: The role of interferon alfa in the treatment of metastatic melanoma. Semin Oncol 1997, 24:S24-S31. The use of interferon alpha as adjuvant therapy for melanoma improves survival rates for high-risk malignant melanoma. The use of combination chemoimmunotherapic therapy that includes interferon alpha may further increase this survival.
68. Stern RS, Weinstein MC, Baker SG: Risk reduction for nonmelanoma skin cancer with childhood sunscreen use. Arch Dermatol 1986, 122:537-545.
69. San Francisco Examiner. Feb. 18, 1998. p. A2.
70. Setlow RB, Woodhead AD: Temporal changes in the incidence of malignant melanoma: Explanation from action spectra. Mutation Res 1994, 307:365-374.
71. Gasparro FP: The molecular basis of UV-induced mutagenesis of sunscreens. FEBS Letters 1993, 336:184-185.
72. McGee R, Williams S, Glasgow H: Sunburn and sun protection among young children. J Paediatr Child Health 1997, 33:234-237. The sun protection practice for 285 children in New Zealand on summer weekends was assessed by phone survey. Parental use of sunscreen was the strongest predictor of sun protection for these children. Approximately half of the children surveyed were adequately protected.
73. Olson AL, Dietrich AJ, Sox CH, Stevens MM: Solar protection of children at the beach. Pediatrics 1997, 99:861.
74. Pion IA, Kopf AW, Hughes BR, Wetton NM, et al.: Teaching children about skin cancer: The draw-and-write technique as an evaluation tool. Pediatric Dermatol 1997, 14:6-12. Perceptions and attitudes toward sun exposure were assessed in children aged 4 to 13 years by their drawing pictures. This method may allow assessment of outcome and cost-effectiveness of sun protection educational programs targeted at children.
75. Hughes BR, Wetton N, Collins M, Bishop JA: Health education about sun and skin cancer: Language, ideas, and perceptions of young children. Br J Dermatol 1996, 134:624-629.
76. Eckhardt L, Mayer JA, Creech L, et al.: Assessing children's ultraviolet radiation exposure: The potential usefulness of a colorimeter. Am J Public Health 1996, 86:1802-1804.
77. Mayer JA, Sallis JF, Eckhardt L, et al.: Assessing children's ultraviolet radiation exposure: The use of parental recall via telephone interviews. Am J Public Health 1997, 87:1046-1049.
78. Miller DR, Geller AC, Wyatt SW, et al.: Melanoma awareness and self-examination practices: Results of a United States survey. J Am Acad Dermatol 1996, 34:962-970. The American Academy of Dermatology has actively promoted melanoma awareness. This study investigated the knowledge of 1001 persons by telephone survey. Knowledge deficiencies in detection of melanoma were evident. This helps support the need for increased public education.
79. Wagner RS: Why children must wear sunglasses. Contemp Pediatrics 1995, 12:27-37.
80. Swerdlow AJ, Weinstock MA: Do tanning lamps cause melanoma? An epidemiologic assessment. J Am Acad Dermatol 1998, 38:89-98.